Cornea/External Disease News

There are two areas I am really excited about specifically in the areas of lid margin disease and dry eye disease.

In dry eye care, 2023 was a year of substantial changes, and ophthalmologists and their patients have welcomed more treatment options that bring relief.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.

Ocular surface disease includes dry eye syndrome, blepharitis/meibomian gland dysfunction, conjunctivitis, keratitis and episcleritis/scleritis.

There is an old saying — it might even be true — that medical students who go into psychiatry do so to figure out what is wrong with them.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Nandini Venkateswaran, MD, shares key points for diagnosing and treating complex cases of neurotrophic keratitis.

A phase 3 clinical trial of tivanisiran failed to meet the primary endpoint in the treatment of dry eye disease associated with Sjörgren’s syndrome, according to a press release from Sylentis.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Jennifer Loh, MD, explains the results of the SAHARA trial comparing TearCare and Restasis for treating dry eye disease.

The FDA cleared an investigational new drug application for OK-101 for the treatment of neuropathic corneal pain, according to a press release from Okyo Pharma.

A 42-year-old man with no significant medical history presented initially in the emergency department of an outside hospital with a 2-week history of progressive bilateral nasal congestion, facial pain and pressure.